CLASS ACTION UPDATE for WWE, AAN and ANAB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / March 27, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

World Wrestling Entertainment, Inc. (NYSE:WWE)
WWE Lawsuit on behalf of: investors who purchased February 7, 2019 – February 5, 2020
Lead Plaintiff Deadline: May 5, 2020
Join the action: https://www.zlk.com/pslra-1/world-wrestling-entertainment-inc-loss-form?wire=3&prid=5829

About the WWE lawsuit: World Wrestling Entertainment, Inc. allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: Defendants perpetrated a fraudulent scheme which: (i) deceived the investing public regarding WWE's business and prospects; (ii) artificially inflated the price of WWE Class A common stock; (iii) permitted certain senior executives of WWE to sell more than $282 million worth of their personally held shares at fraud inflated prices; and (iv) caused the public to purchase WWE Class A common stock at artificially inflated prices.

To learn more about the World Wrestling Entertainment, Inc. class action, contact jlevi@levikorsinsky.com.

Aarons, Inc. (NYSE:AAN)
AAN Lawsuit on behalf of: investors who purchased March 2, 2018 – February 19, 2020
Lead Plaintiff Deadline: April 28, 2020
Join the action: https://www.zlk.com/pslra-1/aarons-inc-loss-form?wire=3&prid=5829

About the AAN lawsuit: Aarons, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Aaron's had inadequate disclosure controls, procedures, and compliance measures; (ii) consequently, the operations of Aaron's Progressive Leasing ("Progressive") and Aaron's Business ("AB") segments were in violation of the Federal Trade Commission ("FTC") Act and/or relevant FTC regulations; (iii) consequently, Aaron's earnings from those segments were partially derived from unlawful business practices and were thus unsustainable; (iv) the full extent of Aaron's liability regarding the FTC's investigation into its Progressive and AB segments, Aaron's noncompliance with the FTC Act, and the likely negative consequences of all the foregoing on the Company's financial results; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

To learn more about the Aarons, Inc. class action, contact jlevi@levikorsinsky.com.

AnaptysBio, Inc. (NASDAQ:ANAB)
ANAB Lawsuit on behalf of: investors who purchased October 10, 2017 – November 7, 2019
Lead Plaintiff Deadline: May 26, 2020
Join the action: https://www.zlk.com/pslra-1/anaptysbio-inc-loss-form?wire=3&prid=5829

About the ANAB lawsuit: AnaptysBio, Inc. allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (i) AnaptysBio failed to disseminate important data from the Company's Phase 2a trial in atopic dermatitis, including the timing and extent of patients' use of topical corticosteroids as a rescue therapy during the study and whether any of the patients that utilized rescue therapy were classified as responders at a given time;and (ii) the Company's statements omitted key information from the Company's Phase 2a trial in peanut allergy, including patients' average cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo as well as whether the Company's decision to exclude 20% of the patients enrolled in the study from the interim analysis due to their mild symptoms was retrospective; and (ii) as a result of the foregoing, Defendants' positive statements about the efficacy and prospects of AnaptysBio's lead drug asset in the treatment of atopic dermatitis and peanut allergy were materially false and/or misleading and/or lacked a reasonable basis.

To learn more about the AnaptysBio, Inc. class action, contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 582832